Literature DB >> 26212030

Prognostic impact of surgery and radiofrequency ablation on single nodular HCC ⩽5 cm: Cohort study based on serum HCC markers.

Masaki Ueno1, Shinya Hayami1, Yoshinobu Shigekawa1, Manabu Kawai1, Seiko Hirono1, Ken-ichi Okada1, Hideyuki Tamai2, Naoki Shingaki2, Yoshiyuki Mori2, Masao Ichinose2, Hiroki Yamaue3.   

Abstract

BACKGROUND & AIMS: Serological markers of hepatocellular carcinoma (HCC) indicate its invasiveness. We aimed to investigate whether the prognostic impact of surgical resection (SR) and radiofrequency thermal ablation (RFA) on patients with single nodular HCC ⩽5cm were different regarding positive conditions of the following three HCC markers: alpha-fetoprotein (AFP); lens culinaris agglutinin-reactive fraction of AFP; and des-γ-carboxy prothrombin.
METHODS: This study reviewed 296 patients with single nodular HCC ⩽5cm with Child-Pugh grade A between 2001 and 2011 (SR, n=136; RFA, n=160). Based on positive conditions of previous HCC markers (defined as non-positive, single-positive, double-positive, and triple-positive), overall survival (OS) and prognostic factors were analyzed.
RESULTS: Five-year OS rates of SR and RFA among all patients were 70.1% and 69.8%, respectively (p=0.14). However, when stratified by the positive conditions of three HCC markers, their rates of non-, single-, double-, and triple-positive patients were 60.6%, 78.2%, 54.2%, and 75.9% in the SR group, whereas rates were 83.3%, 75.7%, 62.2%, and 47.6% in the RFA group (p values between SR and RFA of each tumor marker condition were 0.45, 0.10, 0.77, and <0.01, respectively). Multivariate analyses showed that RFA itself became an independent prognostic factor in the triple-positive group, with an odds ratio of 1.78 (95% confidence interval, 1.16-2.72).
CONCLUSIONS: Positive conditions of three HCC markers differently influenced survival rates of those who underwent SR and RFA when treating single nodular HCC ⩽5cm. RFA itself became an independent prognostic risk when all three HCC markers were positive. Preoperative evaluation of multiple HCC markers might become an index for selecting treatment modalities.
Copyright © 2015 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Hepatocellular carcinoma; Radiofrequency ablation; Surgery; Tumor marker

Mesh:

Substances:

Year:  2015        PMID: 26212030     DOI: 10.1016/j.jhep.2015.07.013

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  23 in total

1.  ASO Author Reflections: A New Look at the Clinical Significance of MVI in Hepatocellular Carcinoma.

Authors:  Derek J Erstad; Kenneth K Tanabe
Journal:  Ann Surg Oncol       Date:  2019-05-20       Impact factor: 5.344

2.  Transient increases in serum α fetoprotein and protein induced by vitamin K antagonist II levels following proton therapy does not necessarily indicate progression of hepatocellular carcinoma.

Authors:  Maiko Yoshida; Hiroyuki Ogino; Hiromitsu Iwata; Yukiko Hattori; Shingo Hashimoto; Koichiro Nakajima; Shigeru Sasaki; Masaki Hara; Yoshitaka Sekido; Jun-Etsu Mizoe; Yuta Shibamoto
Journal:  Oncol Lett       Date:  2019-01-11       Impact factor: 2.967

3.  Utility of percutaneous radiofrequency ablation alone or combined with transarterial chemoembolization for early hepatocellular carcinoma.

Authors:  Tsutomu Tamai; Akihiko Oshige; Kazuaki Tabu; Eriko Tabu; Syo Ijyuin; Haruka Sakae; Hiroka Onishi; Kaori Muromachi; Akiko Saisyoji; Kohei Oda; Kotaro Kumagai; Seiichi Mawatari; Akihiro Moriuchi; Kazuhiro Sakurai; Tsuyoshi Hori; Akio Ido
Journal:  Oncol Lett       Date:  2017-06-23       Impact factor: 2.967

4.  Subclassification of patients with intermediate-stage (Barcelona Clinic Liver Cancer stage-B) hepatocellular carcinoma using the up-to-seven criteria and serum tumor markers.

Authors:  Haruki Kimura; Kazuyoshi Ohkawa; Masanori Miyazaki; Mitsuru Sakakibara; Kazuho Imanaka; Takeshi Tamura; Hironari Sueyoshi; Ryoji Takada; Nobuyasu Fukutake; Hiroyuki Uehara; Reiko Ashida; Tatsuya Ioka; Tetsuro Nakazawa; Katsuyuki Nakanishi; Kazuhiro Katayama
Journal:  Hepatol Int       Date:  2016-10-20       Impact factor: 6.047

5.  A Clinical Scoring System for Predicting Microvascular Invasion in Patients with Hepatocellular Carcinoma Within the Milan Criteria.

Authors:  Tomoki Ryu; Yuko Takami; Yoshiyuki Wada; Masaki Tateishi; Takanobu Hara; Munehiro Yoshitomi; Seiya Momosaki; Kotaro Yasumori; Hideki Saitsu; Koji Okuda
Journal:  J Gastrointest Surg       Date:  2019-02-20       Impact factor: 3.452

Review 6.  Tumor Biomarkers and Interventional Oncology: Impact on Local Outcomes for Liver and Lung Malignancy.

Authors:  Yuan-Mao Lin; Ryosuke Taiji; Marco Calandri; Bruno C Odisio
Journal:  Curr Oncol Rep       Date:  2021-04-15       Impact factor: 5.075

Review 7.  The Number of Positive Tumor Marker Status Is Beneficial for the Selection of Therapeutic Modalities in Patients with Hepatocellular Carcinoma.

Authors:  Toru Beppu; Shigeki Nakagawa; Hidetoshi Nitta; Hirohisa Okabe; Takayoshi Kaida; Katsunori Imai; Hiromitsu Hayashi; Yuki Koga; Kunitaka Kuramoto; Daisuke Hashimoto; Yo-Ichi Yamashita; Akira Chikamoto; Takatoshi Ishiko; Hideo Baba
Journal:  J Clin Transl Hepatol       Date:  2017-05-10

8.  Effectiveness of PIVKA-II in the detection of hepatocellular carcinoma based on real-world clinical data.

Authors:  Rentao Yu; Zhaoxia Tan; Xiaomei Xiang; Yunjie Dan; Guohong Deng
Journal:  BMC Cancer       Date:  2017-09-01       Impact factor: 4.430

9.  Novel treatment strategy with radiofrequency ablation and surgery for pregnant patients with hepatocellular carcinoma: a case report.

Authors:  Megumi Matsuo; Katsunori Furukawa; Hiroaki Shimizu; Hideyuki Yoshitomi; Tsukasa Takayashiki; Satoshi Kuboki; Shigetsugu Takano; Daisuke Suzuki; Nozomu Sakai; Shingo Kagawa; Hiroyuki Nojima; Masayuki Ohsuka
Journal:  Surg Case Rep       Date:  2018-05-02

10.  The β-catenin/TCF-4-LINC01278-miR-1258-Smad2/3 axis promotes hepatocellular carcinoma metastasis.

Authors:  Wei-Juan Huang; Xiao-Peng Tian; Si-Xue Bi; Si-Rui Zhang; Ting-Sha He; Li-Yan Song; Jing-Ping Yun; Zhong-Guo Zhou; Rong-Min Yu; Mei Li
Journal:  Oncogene       Date:  2020-05-05       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.